Getinge Group: Getinge Announces Preliminary Results for 2012

  Getinge Group: Getinge Announces Preliminary Results for 2012

Business Wire

GETINGE, Sweden -- January 11, 2013

Regulatory News:

Demand for the Getinge Group’s (STO:GETIB) products weakened during the final
quarter of 2012, which had an adverse impact on orders received and invoicing
volume. For the full-year, orders received and invoicing rose organically by
nearly 3%, which was lower than the expected volume growth. The demand for
capital goods was particularly weak in Western Europe and Eastern Europe.

Due to lower invoicing volumes during the final quarter of the year,
consolidated net profit before tax fell short of expectations, totaling
approximately SEK 3,600 million for the full-year, excluding acquisition and
restructuring costs related to TSS. As previously announced, acquisition and
restructuring costs of SEK 170 million associated with the purchase of TSS
will be charged to Getinge’s profit for 2012.

This announcement will be followed by a conference call at 2:00 PM (CET),
hosted by Johan Malmquist, CEO, Getinge Group, and Ulf Grunander, CFO, Getinge

Getinge will issue its year-end report for 2012 on January 25.

Conference call

To participate, please call:

In Sweden: +46 8 5352 6408

In the UK: +44 20 7136 2051

In the US: +1 212 444 0481

Participant code: 6776524


1:45 pm – Call the conference number

2:00 pm – Introduction

2:10 pm – Q&A

3:00 pm – End of conference

A recorded version of the conference will be accessible for five working days
at the following number:

Sweden: +46 8 5051 3897

UK: +44 20 3427 0598

US: +1 347 366 9565

Passcode: 6776524

GETINGE GROUP is a leading global provider of products and systems that
contribute to quality enhancement and cost efficiency within healthcare and
life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and
MAQUET. ArjoHuntleigh focuses on patient mobility and wound management
solutions. GETINGE provides solutions for infection control within healthcare
and contamination prevention within life sciences. MAQUET specializes in
solutions, therapies and products for surgical interventions, interventional
cardiology and intensive care.

The information is such that Getinge AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.

This information was brought to you by Cision


Johan Malmquist
CEO, Getinge Group
Telephone: +46 10 335 55 33
Ulf Grunander
CFO, Getinge Group
Telephone: +46 10 335 55 80
Press spacebar to pause and continue. Press esc to stop.